Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.66 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4184481 | 0.98 | SLC6A4 (0.64) | SLC6A4SLC6A2SLC6A3DRD2DRD3 | |
| SCHEMBL22878457 | 0.89 | SLC6A4 (0.70) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL17285874 | 0.89 | SLC6A4 (0.70) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL5433122 | 0.84 | KCNH2 (0.49) | SLC6A4SLC6A2SLC6A3DRD2DRD3 | |
| SCHEMBL10994891 | 0.84 | SLC6A4 (0.79) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL6003999 | 0.84 | KCNH2 (0.49) | SLC6A4SLC6A2SLC6A3DRD2DRD3 | |
| SCHEMBL6003376 | 0.84 | KCNH2 (0.49) | SLC6A4SLC6A2SLC6A3DRD2DRD3 | |
| SCHEMBL3207570 | 0.82 | SLC6A2 (0.54) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL25041083 | 0.82 | SLC6A2 (0.54) | SLC6A4SLC6A2SLC6A3DRD2DRD3 | |
| SCHEMBL11472691 | 0.82 | KCNH2 (0.51) | SLC6A4SLC6A2SLC6A3DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023168298-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-20080176917-A1 | 3-Triazolylthiaalkyl-3-Azabicyclo (3-1-O) Hexanes and Their Use as Dopamine D3 Receptor Ligands | GLAXO GROUP LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
| US-4231935-A | ANXIOLYTICS AND ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1980-11-04 | — | — | US | disclosed |
| US-4196120-A | 1,2-BIS(HYDROCARBYLSULFONYLOXY OR HALO METHYL)CYCLOPROPYLBENZENE, OPTICAL ACITIVITY ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1980-04-01 | — | — | US | disclosed |
| US-4131611-A | ANXIOLYTIC, ANALGESIC | AMERICAN CYANAMID COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176917-A1 | 3-Triazolylthiaalkyl-3-Azabicyclo (3-1-O) Hexanes and Their Use as Dopamine D3 Receptor Ligands | DRD3, HTR3C, HTR5A | SLC6A4 194/4885SLC6A2 338/4885SLC6A3 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.